Non-Hodgkin Lymphoma Diagnostics Market By Type (Lymph Node Biopsy (Immunophenotyping, Cytogenetic Analysis, Gene Expression Profiling, Microarray analysis), (Physical Imaging (MRI Scanning, CT-Scan, X-rays, Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), Blood Tests)), By Type of NHL (B-Cell Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, Mantel Cell Lymphoma, Primary Central Nervous System Lymphoma), (T-Cell Non-Hodgkin Lymphoma (Peripheral T-Cell Lymphoma not Otherwise Specified, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Adult T-Cell Lymphoma, Nasal type NK/T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma), By Category of Condition (Category A, Category B, Category X, Category E), By End User (Hospitals, Diagnostic Centers, Clinics), and Geography.  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Non-Hodgkin Lymphoma Diagnostics Market size was valued at USD 12149.12 million in 2021 and is expected to grow at a CAGR of 10.8% from 2022-2028. Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this. Non-Hodgkin lymphoma is the second most frequent cancer in people with HIV, and some people with AIDS also have lymphoma. It is true that non-Hodgkin lymphoma patients should routinely undergo HIV and hepatitis virus screenings. A thorough assessment of the burden brought on by malignancies was made by the Global Burden of Disease study (GBDs), which made it easier to monitor the temporal patterns in the disease burden. The idea that there is a connection between obesity and NHL has been supported by concurrent rises in the prevalence of obesity and the incidence of NHL during the past few decades. The prognosis for those who have non-lymphoma Hodgkin's has improved as a result of improvements in diagnosis and therapy. Researchers are investigating ways to avoid infections such HHV-8, HIV, HTLV-1, and H. pylori that have been linked to non-Hodgkin lymphoma. The chance of getting non-Hodgkin lymphoma may be decreased by avoiding exposure to certain substances, such as lead, arsenic, pesticides, vinyl chloride, and asbestos.

Recent Market Developments:
In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.

Global Non Hodgkin Lymphoma Diagnostics Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Non-Hodgkin Lymphoma Diagnostics Market Dynamics Drivers And Restraints

Growing awareness and concern about the disease, increase in healthcare expenditure, rise in advancements in the technologies and innovation of new products, large number of unmet needs related to the disease are the few factors which are propelling the growth of the Non-Hodgkin lymphoma diagnostics market. However, limited options for the treatment, inaccurate and inadequate results of the diagnosis, high cost associated with the tests are the few factors which are restraining the growth of the Non-Hodgkin lymphoma diagnostics market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Non Hodgkin Lymphoma Diagnostics Market Segmentation

By Type
  • Lymph Node Biopsy
  • Immunophenotyping
  • Cytogenetic Analysis
  • Gene Expression Profiling
  • Microarray analysis
  • Physical Imaging
  • MRI Scanning
  • CT-Scan
  • X-rays
  • Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
  • Blood Tests
Type of NHL
  • B-Cell Non-Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Burkitt Lymphoma
  • Mantel Cell Lymphoma
  • Primary Central Nervous System Lymphoma
  • T-Cell Non-Hodgkin Lymphoma
  • Peripheral T-Cell Lymphoma not Otherwise Specified
  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T-Cell Lymphoma
  • Enteropathy-Associated T-Cell Lymphoma
  • Adult T-Cell Lymphoma
  • Nasal type NK/T-Cell Lymphoma
  • Hepatosplenic T-Cell Lymphoma
  • Category A
  • Category B
  • Category X
  • Category E
End User
  • Hospitals
  • Diagnostic Centers
  • Clinics


Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.



  • Novartis AG (Switzerland)
  • Amgen, Inc.(U.S)
  • Abbott Laboratories, Inc.(U.S)
  • Eli Lilly and Company(U.S.)
  • AstraZeneca plc (U.K)
  • Illumina, Inc.(U.S)
  • Genoptix, Inc. (U.S.)
  • bioMeriux SA (France)
  • Pfizer, Inc. (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline plc (UK)
  • Celgene corporation (U.S)